News & Research
New studies, trials, regulatory changes and news about the compounds on Amino WRX. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-16.
- Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β-Oxidation in High-Fat Diet-Induced Obesity Mice
J Proteome Res
In mice with diet-induced obesity, semaglutide and tirzepatide reduced hepatic fatty acid uptake and fatty acid oxidation. The paper is laboratory evidence about liver fat handling, not a human trial of liver benefit.
- Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.
Eur Heart J
In an animal model of heart failure with preserved ejection fraction, semaglutide reduced cardiac and hepatic remodelling even when the effect was separated from weight loss. This is laboratory evidence only and does not show that the same benefit occurs in people.
- Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Rapid Communications in Mass Spectrometry
A mass-spectrometry study reports how retatrutide, the compound this site lists as GLP3-R, can be detected in human plasma and urine and describes its excretion profile. The findings matter for sports-drug testing because they show the compound can be identified in biological samples.
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
Lancet
Lancet published the phase 3 ACHIEVE-4 trial of cardiovascular safety for oral orforglipron versus insulin glargine in type 2 diabetes at higher cardiovascular risk. This is the primary citation for any heart-safety statement on the orforglipron page.
- Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.
Nat Med
Nature Medicine published a randomized placebo-controlled trial of semaglutide in type 2 diabetes with kidney disease. This is primary human evidence and should set the kidney-benefit grade on the GLP1-S page.
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Clin Obes
A systematic review pooled head-to-head studies of tirzepatide versus semaglutide for weight loss. Comparative wording on the GLP2-T and GLP1-S pages should follow this human evidence rather than cross-trial claims.
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
N Engl J Med
The New England Journal of Medicine published a trial of once-weekly survodutide in adults with obesity and type 2 diabetes. That paper should be the lead human citation for efficacy and safety on the survodutide page.
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Clin Obes
A systematic review and meta-analysis assessed depression burden and risk in people receiving semaglutide. The GLP1-S psychiatric safety text should be aligned to the pooled result instead of left as anecdote.
- Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.
BMJ Open
A EudraVigilance analysis examined tirzepatide reports tied to suboptimal outcomes and drug-use problems. The GLP2-T safety section should add any disproportionate real-world signals this paper actually identifies.
- Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.
Hum Psychopharmacol
A 12-month real-world cohort tracked renal biomarkers and lithium safety after tirzepatide was started in people with bipolar disorder already on lithium. The GLP2-T safety section should cover this interaction setting and follow the signal the paper actually found.
- Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Contemp Clin Trials
A review covers the mechanism, clinical evidence, and open questions for survodutide in obesity. It is a check on what the page should still call uncertain, not a new trial result.
- Semaglutide Demonstrates Benefits Across Frailty Levels.
JAMA
JAMA reported that semaglutide showed benefits across frailty levels. If the GLP1-S page implies benefit is limited to healthier adults, this human report should be checked before that limitation is kept.
- Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.
JACC Case Rep
A case report describes hemodynamic compromise linked to semaglutide-associated abdominal distension. This is a rare safety signal and should be listed as a single case, not as an expected effect.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
Diabetes Care
This paper estimates tirzepatide MACE benefit in SURPASS-CVOT by imputing a placebo from REWIND, rather than reporting a new outcome trial. The site should not present that estimate as direct evidence of cardiovascular benefit.
- Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging.
Aging Cell
A study reports that elamipretide rejuvenated oocyte quality and restored female fertility during reproductive aging. The listing does not state the model, so the SS-31 page should not add a human fertility benefit until that is confirmed.
- Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Diabetes Obes Metab
A paper reports nephroprotective effects of survodutide in hypertension-accelerated diabetic kidney disease. Confirm whether it is human or animal before it is allowed to change the kidney grade on the survodutide page.